Can a gene test tell who will benefit from immunotherapy?
NCT ID NCT04953104
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This study looks at whether certain genetic changes in tumors can help predict how well the immunotherapy drug nivolumab works for people with advanced bladder cancer that has spread. Researchers are focusing on two genes, ARID1A and KDM6A, and a protein called CXCL13. The goal is to find better ways to choose which patients are most likely to benefit from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.